PL439780A1 - Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy - Google Patents

Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy

Info

Publication number
PL439780A1
PL439780A1 PL439780A PL43978021A PL439780A1 PL 439780 A1 PL439780 A1 PL 439780A1 PL 439780 A PL439780 A PL 439780A PL 43978021 A PL43978021 A PL 43978021A PL 439780 A1 PL439780 A1 PL 439780A1
Authority
PL
Poland
Prior art keywords
methoxyestradiol
mastocytosis
treatment
cutaneous
subject
Prior art date
Application number
PL439780A
Other languages
English (en)
Other versions
PL244930B1 (pl
Inventor
Magdalena Górska-Ponikowska
Iwona PELIKANT-MAŁECKA
Paulina BASTIAN
Marek NIEDOSZYTKO
Bogusław Niedoszytko
Leszek KALINOWSKI
Michał WOŹNIAK
Magdalena LANGE
Marta GRUCHAŁA-NIEDOSZYTKO
Roman Nowicki
Aleksandra GÓRSKA
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL439780A priority Critical patent/PL244930B1/pl
Priority to PCT/PL2022/050091 priority patent/WO2023106947A1/en
Priority to EP22847278.3A priority patent/EP4436582B1/en
Publication of PL439780A1 publication Critical patent/PL439780A1/pl
Publication of PL244930B1 publication Critical patent/PL244930B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Przedmiotem zgłoszenia jest 2-metoksyestradiol do zastosowania w leczeniu mastocytozy, zwłaszcza jej postaci skórnej i/lub postaci układowej.
PL439780A 2021-12-08 2021-12-08 Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy PL244930B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL439780A PL244930B1 (pl) 2021-12-08 2021-12-08 Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
PCT/PL2022/050091 WO2023106947A1 (en) 2021-12-08 2022-12-08 Use of 2-methoxyestradiol in the treatment of mastocytosis
EP22847278.3A EP4436582B1 (en) 2021-12-08 2022-12-08 2-methoxyestradiol for use in the treatment of mastocytosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL439780A PL244930B1 (pl) 2021-12-08 2021-12-08 Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy

Publications (2)

Publication Number Publication Date
PL439780A1 true PL439780A1 (pl) 2023-06-12
PL244930B1 PL244930B1 (pl) 2024-04-02

Family

ID=85036942

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439780A PL244930B1 (pl) 2021-12-08 2021-12-08 Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy

Country Status (3)

Country Link
EP (1) EP4436582B1 (pl)
PL (1) PL244930B1 (pl)
WO (1) WO2023106947A1 (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923376B1 (en) * 1996-05-09 2004-11-03 Amrad Operations Pty.,Ltd. Use of steroids for treatment of asthma and airway diseases
DK1084146T3 (da) 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
JP2003009883A (ja) 2001-07-05 2003-01-14 Mitsubishi Pharma Corp マスト細胞の細胞死誘発剤
CA2615598C (en) * 2005-07-20 2014-04-15 Peter Valent Compositions for treatment of systemic mastocytosis
FR2981945B1 (fr) 2011-11-02 2016-09-23 Centre Nat Rech Scient Lignees de mastocytes humains, preparation et utilisations
WO2014188423A1 (en) 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
EP3512515A1 (en) * 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
KR102867888B1 (ko) * 2018-01-31 2025-10-13 데시페라 파마슈티칼스, 엘엘씨 비만 세포증의 치료를 위한 병용 요법
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis

Also Published As

Publication number Publication date
EP4436582B1 (en) 2025-04-02
EP4436582A1 (en) 2024-10-02
WO2023106947A1 (en) 2023-06-15
EP4436582C0 (en) 2025-04-02
PL244930B1 (pl) 2024-04-02

Similar Documents

Publication Publication Date Title
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2021002664S1 (es) Pieza para aparato de aseo personal. (divisional solicitud 202002626)
MX2020011857A (es) Composiciones refrigerantes estabilizadas de fluoroolefina y metodos para su produccion, almacenamiento y uso.
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
JOP20210324A1 (ar) مشتقات من 2h-indazole واستخدامها في علاج مرض
JP2025505052A (ja) Ａｔｐ合成酵素の阻害剤－美容および治療への使用
MX2020002823A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
EP3876935A4 (en) TOPICAL FORMULATIONS OF 5-A REDUCTASE INHIBITORS AND THEIR USES
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
MX2022016496A (es) Combinacion de un inhibidor del bromodominio cbp/p300 y un inhibidor del egfr para su uso en el tratamiento de la cpnm con mutacion del egfr.
MX392976B (es) Composiciones que comprenden cepas bacterianas.
PL439780A1 (pl) Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
EP3672994A4 (en) HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME
MX2022003396A (es) Uso de inhibidores de dkk-1 para tratar el cancer.
MX2021005766A (es) Métodos de gestión de eventos adversos en pacientes con inflamación.
MX2020010338A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
MX2024014771A (es) Terapia combinada
PL445003A1 (pl) Kompozycja farmaceutyczna, zwłaszcza do leczenia nowotworów i jej zastosowanie
PL130737U1 (pl) Układ sortujący
EA202091933A1 (ru) Композиция для предупреждения и лечения нарушений роста волос
MX2023006076A (es) Derivados de cannabinoides y su uso en el tratamiento de la inflamación y/o el dolor y/o la obesidad.
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
PE20250073A1 (es) Formulacion de sotorasib